Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87084 trials found · Page 96 of 4355
-
Major heart study aims to tame a hidden killer
Disease control OngoingThis is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Engineered immune cells injected directly into the brain to fight childhood tumors
Disease control Recruiting nowThis is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the …
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
New drug shows promise in taming devastating autoimmune nerve attacks
Disease control CompletedThe primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
Massive study aims to stop gallbladder cancer before it starts
Prevention Recruiting nowGallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC). Currently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker avail…
Sponsor: Centre Paul Strauss • Aim: Prevention
Last updated Apr 22, 2026 15:59 UTC
-
Brain cancer breakthrough? new drug shows promise in Mid-Stage trial
Disease control OngoingThe proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy …
Phase: PHASE2, PHASE3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New shot every 3 months could extend life for rare heart disease patients
Disease control OngoingThis study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
New hope for Drug-Resistant HIV: Long-Acting shot shows promise
Disease control OngoingThe primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency virus type 1 (HIV-1) (PWH) with multi-drug resista…
Phase: PHASE2, PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Light vs. germs: can a flash make blood safer?
Prevention CompletedThis is a prospective, randomized, double-blind, controlled study to determine the effectiveness of Mirasol-treated fresh whole blood (FWB) versus Standard-issue FWB for preventing transmission of transfusion-transmitted infections (TTIs). The incidence of pre-defined viral, bact…
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Apr 15, 2026 16:14 UTC
-
Daily shot aims to stop bleeds in haemophilia patients
Disease control OngoingThis study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bl…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Freeze and boost: new combo attack on tough breast cancer before surgery
Disease control OngoingThe purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after ta…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Sibling's stem cells may free kidney patients from lifelong drugs
Disease control Recruiting nowThe purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor. The …
Phase: PHASE1, PHASE2 • Sponsor: Jeffrey Veale, MD • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Could a simple pill replace the shot for gonorrhea?
⭐️ CURE ⭐️ CompletedThis trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azi…
Phase: PHASE3 • Sponsor: Global Antibiotics Research and Development Partnership • Aim: ⭐️ CURE ⭐️
Last updated Apr 28, 2026 16:02 UTC
-
Immunotherapy combo may keep lung cancer at bay after surgery
Disease control OngoingThe main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Cancer-Free patients test stopping myeloma drugs in groundbreaking trial
Disease control OngoingThis study is to assess for Measurable Residual Disease (MRD) in multiple myeloma at a deeper level than what is currently available by combining novel imaging and laboratory techniques, determine if patients who are MRD-negative by these multiple modalities can safely and effect…
Phase: NA • Sponsor: University of Chicago • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC
-
Drug aims to stop deadly skin cancer's comeback after surgery
Disease control OngoingThe purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New drug shows promise for rare childhood cancers
Disease control OngoingThis phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking th…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
Second chance transplant aims to stop sickle cell disease from coming back
Disease control Recruiting nowBackground: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some donor cells in their body. Objective: To cure peopl…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
New drug duo challenges chemotherapy for Tough-to-Treat uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New drug combo aims to stop aggressive lymphoma from returning
Disease control OngoingThis phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by blocking …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Genetic vaccine shows promise against Hard-to-Treat cancers
⭐️ VACCINE ⭐️ OngoingRef: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vacc…
Phase: PHASE1, PHASE2 • Sponsor: Nouscom SRL • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 26, 2026 19:38 UTC